Internal Medicine, Infectious Disease · Pasadena, TX
NPI
1780622928
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
6319 Fairmont Pkwy, Suite 201
Pasadena, TX, 77505
Phone (281) 991-7999
Groups this clinician bills Medicare through
Medicare paid, 2024
$423K
58,506 services
Medicare patients, 2024
715
Average age 73
Drug cost, 2024
$1.6M
2,208 prescriptions
Company payments, 2025
$886
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Zaher Shebib was code J1306 (injection, inclisiran, 1 mg), 8,804 times for 22 patients. In total Zaher Shebib billed 58,506 services in 28 codes, and Medicare paid $423K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1306 Injection, inclisiran, 1 mg | Office | 8,804 | 22 | $9.50 | $84K |
| 99232 Hospital E&M - Subsequent | Facility | 3,553 | 539 | $58.19 | $207K |
| 99222 Hospital E&M - Initial | Facility | 721 | 575 | $95.72 | $69K |
| 99231 Hospital E&M - Subsequent | Facility | 695 | 249 | $36.41 | $25K |
| 99213 Office E&M - Established | Office | 328 | 153 | $64.27 | $21K |
| 96372 Injection Administration | Office | 32 | 23 | $9.86 | $316 |
| 99203 Office E&M - New | Office | 27 | 27 | $79.34 | $2,142 |
By year: 2022 $473K for 10,230 services; 2023 $422K for 12,674 services; 2024 $423K for 58,506 services.
Medicare prescription drug claims, 2024
In 2024, the drug Zaher Shebib prescribed most often to Medicare patients was Methenamine Hippurate, with 215 prescriptions and refills. In total Zaher Shebib wrote 2,208 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methenamine Hippurate Generic | 215 | 460 | 78 | $22K |
| Ceftriaxone Ceftriaxone Sodium | 196 | 196 | 39 | $22K |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 183 | 187 | 24 | $787K |
| Doxycycline Hyclate Generic | 166 | 204 | 73 | $4,300 |
| Cephalexin Generic | 119 | 185 | 62 | $3,723 |
| Ciprofloxacin Hcl Generic | 80 | 103 | 50 | $1,396 |
| Daptomycin Generic | 78 | 78 | 15 | $60K |
| Vancomycin Hcl Generic | 61 | 63 | 16 | $11K |
| Azithromycin Generic | 51 | 91 | 21 | $853 |
| Meropenem Generic | 50 | 50 | 18 | $14K |
| Fluconazole Generic | 43 | 73 | 25 | $2,311 |
| Cefazolin Sodium Generic | 42 | 42 | Under 11 | $1,881 |
| Cefuroxime Cefuroxime Axetil | 32 | 36 | 17 | $872 |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 31 | 31 | Under 11 | $129K |
| Amikacin Sulfate Generic | 31 | 31 | Under 11 | $780 |
Brand drugs: 364 claims; generic drugs: 1,844 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Zaher Shebib $886 ($886 in general payments such as food, travel and fees) from 10 companies. The largest payer was Gilead Sciences, Inc. with $232.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 9 | $232 |
| ViiV Healthcare Company GSK | 10 | $176 |
| EMD Serono, Inc. MRK.DE | 3 | $128 |
| Abbvie Inc. ABBV | 5 | $95.37 |
| Pfizer Inc. PFE | 3 | $72.41 |
| Insmed, Inc. INSM | 3 | $69.97 |
| Invivyd Inc IVVD | 2 | $48.03 |
| Cumberland Pharmaceuticals, Inc. CPIX | 1 | $24.79 |
| Merck Sharp & Dohme LLC MRK | 1 | $24.14 |
| Ferring Pharmaceuticals Inc. | 1 | $14.89 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.